Navigation Links
Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
Date:4/30/2012

ous positions, including Chief Executive Officer from April 1998 to January 2009. Dr. Carter first joined ZymoGenetics in 1986 as Vice President of Research and Development. In 1988, Novo Nordisk A/S acquired ZymoGenetics, and in 1994, Dr. Carter was promoted to Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom®. Dr. Carter also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a Lecturer at Trinity College, University of Dublin from 1975 to 1982. He received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

About Regulus Therapeutics Inc.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years and tested in more than 5,000 humans. The company works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (NASDAQ: ALNY) and Isis Pharmaceuticals (NASDAQ: ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including fibrosis, hepatitis C, immuno-inflammatory diseases, metabolic diseases and oncology. Regulus' intellectual property estate contains both the fundamental and core patents in the field and includes over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modificat
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
2. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
3. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
4. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
10. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
11. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic ... company developing novel anti-infective biologic and drug programs ... diseases, announced today that its novel C. ... the 54 th Interscience Conference on Antimicrobial ... Washington D.C. Synthetic ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
... JENA, Germany, April 17 Occlutech GmbH, the leading,European ... a recent news release., In a news release ... opinion from AIPPI the European "Association for the Protection,of ... of,certain European IP held by AGA Medical., AIPPI ...
... April 17 BioMed Realty Trust, Inc.,(NYSE: BMR ... of 5,700,000,shares of common stock at $25.50 per share. ... 22, 2008. Gross proceeds from the offering will be,approximately ... of the,offering to repay a portion of the outstanding ...
Cached Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 3
(Date:8/19/2014)... to encourage healthier spending habits? A new study by ... by tracking the purchasing records in a supermarket chain ... nutritional value of foods for sale. , The researchers, ... and Brian Wansink PhD, author of Slim by Design ... Supermarkets in the Northeastern United States between January 2005 ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... American scientists have rediscovered a highly distinctive mammal C a ... years ago. Furthermore, it has never before been discovered in ... extinct. , The greater dwarf cloud rat (Carpomys melanurus) has ... eyes, small rounded ears, a broad and blunt snout, and ...
... throughout the sciences in the study of biological, technological, ... to visualize or understand. In a May 1 ... links in networks, Santa Fe Institute (SFI) researchers Aaron ... real-world networks can be understood as a hierarchy of ...
... Iowa and HOUSTON, Texas The first year ... at Iowa State University (ISU) has supported 26 ... to further diversify Americas sources of energy and ... third-largest integrated energy company in the United States, ...
Cached Biology News:Dwarf cloud rat rediscovered after 112 years 2Dwarf cloud rat rediscovered after 112 years 3Nature paper describes technique for extracting hierarchical structure of networks 2Iowa State-ConocoPhillips collaboration advances 26 research projects in first year 2
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
... Rhesus Serum • Rhesus serum is collected ... 5-7 years of age. Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
... DCTD_HUMAN GI Number: 4503277 ... Description: FUNCTION: Supplies the nucleotide ... dCMP + H 2 O = ... Homohexamer. SIMILARITY: Belongs to the Diseases: ...
Biology Products: